Lv1
38 积分 2025-04-29 加入
The landscape of CAR T‐cell therapy in the United States and China: A comparative analysis
12天前
已完结
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis
18天前
已完结
Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma
19天前
已完结
Twenty years since Joinpoint 1.0: Two major enhancements, their justification, and impact
21天前
已完结
Permutation tests for joinpoint regression with applications to cancer rates
21天前
已完结
Projecting the future burden of cancer: Bayesian age–period–cohort analysis with integrated nested Laplace approximations
21天前
已完结
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
1个月前
已完结
Abstract CT070: Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion
1个月前
已关闭
Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors
1个月前
已关闭
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
1个月前
已完结
皖公网安备34019202002308
